Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Arthritis & Rheumatology

• Publication date

  2017-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/art.39818PMID 27429362PMCID PMC5195893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice

  2015cited by this paper
• Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

  2015cited by this paper
• Targeting of type I interferon in systemic autoimmune diseases.

  2015cited by this paper
• Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice[S]

  2015cited by this paper
• Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon α on lupus endothelial cell progenitors.

  2015cited by this paper
• Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus.

  2015cited by this paper
• Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib†, ‡

  2015cited by this paper
• Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS)

  2015cited by this paper
• Development of Th17‐Associated Interstitial Kidney Inflammation in Lupus‐Prone Mice Lacking the Gene Encoding STAT‐1

  2015cited by this paper
• The JAK-STAT pathway: impact on human disease and therapeutic intervention.

  2015cited by this paper
• Immunoglobulin E plays an immunoregulatory role in lupus

  2014cited by this paper
• Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

  2014cited by this paper
• Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice

  2014influential reference
• Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare

  2014cited by this paper
• Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

  2014cited by this paper
• IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes.

  2014cited by this paper
• Deficiency in Type I Interferon Signaling Prevents the Early Interferon–Induced Gene Signature in Pancreatic Islets but Not Type 1 Diabetes in NOD Mice

  2014cited by this paper
• Anti-interferon alpha treatment in SLE.

  2013cited by this paper
• Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus

  2013cited by this paper
• Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus.

  2013cited by this paper
• Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib

  2013cited by this paper
• The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

  2013cited by this paper
• Mechanisms of disease for the clinician: systemic lupus erythematosus.

  2013cited by this paper
• Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus.

  2013cited by this paper
• Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice.

  2012cited by this paper
• A novel pathogenetic concept—antiviral immunity in lupus nephritis

  2012cited by this paper
• STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction

  2012cited by this paper
• Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis.

  2012cited by this paper
• Murine Models of Systemic Lupus Erythematosus

  2011cited by this paper
• Neutrophils in the pathogenesis and manifestations of SLE

  2011influential reference
• Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

  2011cited by this paper
• Cytokines as therapeutic targets in SLE

  2010cited by this paper
• A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs

  2010cited by this paper
• The Detrimental Effects of IFN-α on Vasculogenesis in Lupus Are Mediated by Repression of IL-1 Pathways: Potential Role in Atherogenesis and Renal Vascular Rarefaction

  2010cited by this paper
• IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice.

  2009cited by this paper
• The Role of IL-23/IL-17 Axis in Lupus Nephritis1

  2009cited by this paper
• Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity.

  2008cited by this paper
• The JAK kinase inhibitor CP‐690,550 supresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

  2008cited by this paper
• Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys1

  2008cited by this paper
• Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

  2007cited by this paper
• Janus kinase 3 inhibition with CP‐690,550 prevents allograft vasculopathy

  2006cited by this paper
• Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus

  2005cited by this paper
• Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.

  2005cited by this paper
• Ultrastructural lupus band test in the skin of MRL mice

  2004cited by this paper
• Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus

  2003cited by this paper
• Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients

  2003cited by this paper
• Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

  2003cited by this paper
• Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

  2003cited by this paper
• T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells

  2001cited by this paper
• Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

  2001cited by this paper
• T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells.

  2001cited by this paper
• Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus.

  1999cited by this paper
• Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

  1991cited by this paper
• [The relationship between murine lupus nephritis and thymic abnormalities].

  1984cited by this paper
• Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains

  1978cited by this paper
• [Erythematosus].

  1971cited by this paper

• JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren’s disease murine model

  2026cites this paper
• Management strategies for systemic lupus erythematosus using kinase inhibitors

  2026cites this paper
• The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases

  2025cites this paper
• Neutrophil extracellular traps and neuropsychiatric lupus: Signaling pathways involved in NET formation and mechanisms affecting the central nervous system.

  2025cites this paper
• Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism

  2025cites this paper
• Interaction of low-density neutrophils with other immune cells in the mechanism of inflammation

  2025cites this paper
• JAK-STAT Signaling in Autoimmunity and Cancer

  2025cites this paper
• Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis

  2025cites this paper
• Tofacitinib for the treatment of severe rare skin diseases: a narrative review

  2024cites this paper
• Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies

  2024cites this paper
• SHR0302 Improves Treg/Th17 Imbalance in Patients with Systemic Lupus Erythematosus

  2024cites this paper
• A case report of systemic lupus erythematosus complicating interstitial lung disease and thickened pericardium treated with tofacitinib

  2024cites this paper
• Dexamethasone’s Clinical Efficacy in Experimental Autoimmune Pancreatitis Correlates with a Unique Transcriptomic Signature, Whilst Kinase Inhibitors Are Not Effective

  2024cites this paper
• Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study

  2024cites this paper
• The role of vitamin D: a promising pathway to combat neuropsychiatric lupus disorders.

  2024cites this paper
• A double‐blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis

  2024cites this paper
• JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases.

  2024cites this paper
• Neutrophils: a key component in ECMO-related acute organ injury

  2024cites this paper
• Beneficial effects of rapamycin on endothelial function in systemic lupus erythematosus

  2024cites this paper
• Unveiling the nexus: Decoding interactions between regulated cell death and systemic lupus erythematosus pathogenesis for innovative therapeutic avenues

  2024cites this paper
• Effects of Dietary Oleacein Treatment on Endothelial Dysfunction and Lupus Nephritis in Balb/C Pristane-Induced Mice

  2023cites this paper
• Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus.

  2023cites this paper
• Perivascular adipose tissue promotes vascular dysfunction in murine lupus

  2023cites this paper
• JAK inhibitors and autoimmune rheumatic diseases.

  2023cites this paper
• JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

  2023cites this paper
• The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Systemic Lupus Erythematosus and Antiphospholipid Syndrome

  2023cites this paper
• The intricate relationship between autoimmunity disease and neutrophils death patterns: a love-hate story

  2023cites this paper
• NETosis: an emerging therapeutic target in renal diseases

  2023cites this paper
• Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus

  2023cites this paper
• Comorbidity in children with rheumatic diseases: literature review and 10-year experience of own research

  2023cites this paper
• Molecular Mechanisms of Neutrophil Extracellular Trap (NETs) Degradation

  2023cites this paper
• Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline

  2023cites this paper
• NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19.

  2023cites this paper
• B Cell Tolerance and Targeted Therapies in SLE

  2023cites this paper
• Further insight into systemic sclerosis from the vasculopathy perspective.

  2023cites this paper
• SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis

  2023cites this paper
• Endothelial Glycocalyx Injury in SARS-CoV-2 Infection: Molecular Mechanisms and Potential Targeted Therapy

  2023cites this paper
• Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.

  2023cites this paper
• MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS

  2023cites this paper
• JAKINIBS IN SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT INSIGHTS AND FUTURE PROSPECTS

  2023cites this paper
• Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition

  2023cites this paper
• JAKinibs prevent persistent, IFNγ-autonomous endothelial cell inflammation and immunogenicity.

  2023cites this paper
• Identification of polo‐like kinase 1 as a therapeutic target in murine lupus

  2022cites this paper
• Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus

  2022cites this paper
• Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus

  2022cites this paper
• Therapeutic Effects of Tofacitinib on Pristane-Induced Murine Lupus

  2022cites this paper
• Cognitive improving actions of tofacitinib in a mouse model of Alzheimer disease involving TNF-α, IL-6, PI3K-Akt and GSK-3β signalling pathway

  2022cites this paper
• Modulation of the Itaconate Pathway Attenuates Murine Lupus

  2022cites this paper
• Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus

  2022cites this paper
• Treatment of cutaneous lupus with topical ruxolitinib cream

  2022cites this paper
• Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?

  2022cites this paper
• Low‐density granulocytes in systemic autoimmunity and autoinflammation

  2022cites this paper
• IFN-γ, should not be ignored in SLE

  2022cites this paper
• Paeoniflorin Inhibits LPS-Induced Activation of Splenic CD4+ T Lymphocytes and Relieves Pathological Symptoms in MRL/lpr Mice by Suppressing IRAK1 Signaling

  2022cites this paper
• Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus.

  2022cites this paper
• Advances in Immunosuppressive Agents Based on Signal Pathway

  2022cites this paper
• Late phase endothelial cell inflammation is characterized by interferon response genes and driven by JAK/STAT, not NFκB.

  2022cites this paper
• The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (NETs) in the pathogenesis of primary Sjögren’s syndrome

  2022cites this paper
• Endothelial function and endothelial progenitor cells in systemic lupus erythematosus

  2022cites this paper
• The Impact of Cytokines on Neutrophils’ Phagocytosis and NET Formation during Sepsis—A Review

  2022cites this paper
• Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus

  2022cites this paper
• Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases

  2022cites this paper
• Lupus Nephritis: Current Perspectives and Moving Forward

  2022cites this paper
• Diverse Roles of NETosis in the Pathogenesis of Lupus

  2022cites this paper
• Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus

  2022cites this paper
• CD3+CD4+gp130+ T Cells Are Associated With Worse Disease Activity in Systemic Lupus Erythematosus Patients

  2021cites this paper
• Novel Therapeutic Strategy Based on Neutrophil Subset and Its Function in Autoimmune Disease

  2021cites this paper
• Casting a NET on cancer: the multiple roles for neutrophil extracellular traps in cancer

  2021cites this paper
• Patients with COVID-19: in the dark-NETs of neutrophils

  2021cites this paper
• Cardiovascular disease in lupus

  2021cites this paper
• Shared inflammatory and skin-specific gene signatures reveal common drivers of discoid lupus erythematosus in canines, humans and mice

  2021cites this paper
• Mechanisms of vascular damage in systemic lupus erythematosus

  2021cites this paper
• Polymorphonuclear cells

  2021cites this paper
• Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation

  2021cites this paper
• Interferon lambda in inflammation and autoimmune rheumatic diseases

  2021cites this paper
• ЗВ’ЯЗОК ХВОРОБ ПАРОДОНТА З СОМАТИЧНИМИ ЗАХВОРЮВАННЯМИ (ОГЛЯД ЛІТЕРАТУРИ)

  2021cites this paper
• Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib

  2021influential citation
• Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

  2021cites this paper
• JAK inhibitors: Ten years after

  2021cites this paper
• Neutrophil Extracellular Traps: Inflammation and Biomaterial Preconditioning for Tissue Engineering

  2021cites this paper
• Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL/lpr mouse autoimmune model

  2021cites this paper
• Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential.

  2021cites this paper
• Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus

  2021cites this paper
• T-cell biology, tolerance, and regulation

  2021cites this paper
• A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.

  2021cites this paper
• The Dual Role of Platelets in the Cardiovascular Risk of Chronic Inflammation

  2021cites this paper
• Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erytheematosus: A systematic review.

  2021cites this paper
• Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

  2021cites this paper
• The role for JAK Inhibitors in the Treatment of Immune-Mediated Rheumatic and related conditions.

  2021cites this paper
• JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis

  2021cites this paper
• Interferons in Systemic Lupus Erythematosus.

  2021cites this paper
• Neutrophil Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus.

  2021cites this paper
• Bite of the wolf: innate immune responses propagate autoimmunity in lupus.

  2021cites this paper
• Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention

  2021cites this paper
• Full Title: Endothelial Resolution of Inflammation is Delayed Following JAK-driven but not NFκB-

  2021cites this paper
• Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor

  2021cites this paper
• The interplay between neutrophils, complement, and microthrombi in COVID-19

  2021cites this paper
• Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression.

  2021cites this paper
• Innovative Trials and New Opportunities in SLE.

  2021cites this paper
• Tissue injury—the biology

  2021cites this paper